Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigen

Lavakumar Karyampudi, Christopher J. Krco, Kimberly R. Kalli, Courtney L. Erskine, Lynn C. Hartmann, Karin Goodman, James N. Ingle, Matthew J. Maurer, Aziza Nassar, Chao Yu, Mary L. Disis, Peter J. Wettstein, John D. Fikes, Melanie Beebe, Glenn Ishioka, Keith L Knutson

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

CD4 T cells are important for anti-tumor immune responses. Aside from their role in the activation of CD8 T cells, CD4 T cells also mediate anti-tumor immune responses by recruiting innate immune effectors into the tumor microenvironment. Thus, the search for strategies to boost CD4 T cell immunity is an active area of research. Our goal in this study was to identify HLA-DR epitopes of carcinoembryonic antigen (CEA), a commonly over-expressed tumor antigen. HLA-DR epitopes of CEA were identified using the epitope prediction program, PIC (predicted IC50) and tested using in vitro HLA-DR binding assays. Following CEA epitope confirmation, IFN-γ ELIspot assays were used to detect existing immunity against the HLA-DR epitope panel of CEA in breast and ovarian cancer patients. In vitro generated peptide-specific CD4 T cells were used to determine whether the epitopes are naturally processed from CEA protein. Forty-three epitopes of CEA were predicted, 15 of which had high binding affinity for 8 or more common HLA-DR molecules. A degenerate pool of four, HLA-DR restricted 15 amino acid epitopes (CEA.24, CEA.176/354, CEA.488, and CEA.653) consisting of two novel epitopes (CEA.24 and CEA.488) was identified against which 40% of breast and ovarian cancer patients had pre-existent T cell immunity. All four epitopes are naturally processed by antigen-presenting cells. Hardy-Weinberg analysis showed that the pool is useful in ~94% of patients. Patients with breast or ovarian cancer demonstrate pre-existent immune responses to the tumor antigen CEA. The degenerate pool of CEA peptides may be useful for augmenting CD4 T cell immunity.

Original languageEnglish (US)
Pages (from-to)161-171
Number of pages11
JournalCancer Immunology, Immunotherapy
Volume59
Issue number1
DOIs
StatePublished - Jan 2010

Fingerprint

Carcinoembryonic Antigen
HLA-DR Antigens
Epitopes
T-Lymphocytes
Ovarian Neoplasms
Immunity
Neoplasm Antigens
Breast Neoplasms
Innate Immunity
Active Immunity
Peptides
Tumor Microenvironment
Antigen-Presenting Cells
Inhibitory Concentration 50
Neoplasms
Amino Acids

Keywords

  • Helper T cells
  • HLA-DR
  • MHC class II
  • Peptides
  • Vaccines

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Immunology
  • Immunology and Allergy

Cite this

Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigen. / Karyampudi, Lavakumar; Krco, Christopher J.; Kalli, Kimberly R.; Erskine, Courtney L.; Hartmann, Lynn C.; Goodman, Karin; Ingle, James N.; Maurer, Matthew J.; Nassar, Aziza; Yu, Chao; Disis, Mary L.; Wettstein, Peter J.; Fikes, John D.; Beebe, Melanie; Ishioka, Glenn; Knutson, Keith L.

In: Cancer Immunology, Immunotherapy, Vol. 59, No. 1, 01.2010, p. 161-171.

Research output: Contribution to journalArticle

Karyampudi, L, Krco, CJ, Kalli, KR, Erskine, CL, Hartmann, LC, Goodman, K, Ingle, JN, Maurer, MJ, Nassar, A, Yu, C, Disis, ML, Wettstein, PJ, Fikes, JD, Beebe, M, Ishioka, G & Knutson, KL 2010, 'Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigen', Cancer Immunology, Immunotherapy, vol. 59, no. 1, pp. 161-171. https://doi.org/10.1007/s00262-009-0738-z
Karyampudi, Lavakumar ; Krco, Christopher J. ; Kalli, Kimberly R. ; Erskine, Courtney L. ; Hartmann, Lynn C. ; Goodman, Karin ; Ingle, James N. ; Maurer, Matthew J. ; Nassar, Aziza ; Yu, Chao ; Disis, Mary L. ; Wettstein, Peter J. ; Fikes, John D. ; Beebe, Melanie ; Ishioka, Glenn ; Knutson, Keith L. / Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigen. In: Cancer Immunology, Immunotherapy. 2010 ; Vol. 59, No. 1. pp. 161-171.
@article{81f48e966413440b90583d4402249db8,
title = "Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigen",
abstract = "CD4 T cells are important for anti-tumor immune responses. Aside from their role in the activation of CD8 T cells, CD4 T cells also mediate anti-tumor immune responses by recruiting innate immune effectors into the tumor microenvironment. Thus, the search for strategies to boost CD4 T cell immunity is an active area of research. Our goal in this study was to identify HLA-DR epitopes of carcinoembryonic antigen (CEA), a commonly over-expressed tumor antigen. HLA-DR epitopes of CEA were identified using the epitope prediction program, PIC (predicted IC50) and tested using in vitro HLA-DR binding assays. Following CEA epitope confirmation, IFN-γ ELIspot assays were used to detect existing immunity against the HLA-DR epitope panel of CEA in breast and ovarian cancer patients. In vitro generated peptide-specific CD4 T cells were used to determine whether the epitopes are naturally processed from CEA protein. Forty-three epitopes of CEA were predicted, 15 of which had high binding affinity for 8 or more common HLA-DR molecules. A degenerate pool of four, HLA-DR restricted 15 amino acid epitopes (CEA.24, CEA.176/354, CEA.488, and CEA.653) consisting of two novel epitopes (CEA.24 and CEA.488) was identified against which 40{\%} of breast and ovarian cancer patients had pre-existent T cell immunity. All four epitopes are naturally processed by antigen-presenting cells. Hardy-Weinberg analysis showed that the pool is useful in ~94{\%} of patients. Patients with breast or ovarian cancer demonstrate pre-existent immune responses to the tumor antigen CEA. The degenerate pool of CEA peptides may be useful for augmenting CD4 T cell immunity.",
keywords = "Helper T cells, HLA-DR, MHC class II, Peptides, Vaccines",
author = "Lavakumar Karyampudi and Krco, {Christopher J.} and Kalli, {Kimberly R.} and Erskine, {Courtney L.} and Hartmann, {Lynn C.} and Karin Goodman and Ingle, {James N.} and Maurer, {Matthew J.} and Aziza Nassar and Chao Yu and Disis, {Mary L.} and Wettstein, {Peter J.} and Fikes, {John D.} and Melanie Beebe and Glenn Ishioka and Knutson, {Keith L}",
year = "2010",
month = "1",
doi = "10.1007/s00262-009-0738-z",
language = "English (US)",
volume = "59",
pages = "161--171",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "1",

}

TY - JOUR

T1 - Identification of a broad coverage HLA-DR degenerate epitope pool derived from carcinoembryonic antigen

AU - Karyampudi, Lavakumar

AU - Krco, Christopher J.

AU - Kalli, Kimberly R.

AU - Erskine, Courtney L.

AU - Hartmann, Lynn C.

AU - Goodman, Karin

AU - Ingle, James N.

AU - Maurer, Matthew J.

AU - Nassar, Aziza

AU - Yu, Chao

AU - Disis, Mary L.

AU - Wettstein, Peter J.

AU - Fikes, John D.

AU - Beebe, Melanie

AU - Ishioka, Glenn

AU - Knutson, Keith L

PY - 2010/1

Y1 - 2010/1

N2 - CD4 T cells are important for anti-tumor immune responses. Aside from their role in the activation of CD8 T cells, CD4 T cells also mediate anti-tumor immune responses by recruiting innate immune effectors into the tumor microenvironment. Thus, the search for strategies to boost CD4 T cell immunity is an active area of research. Our goal in this study was to identify HLA-DR epitopes of carcinoembryonic antigen (CEA), a commonly over-expressed tumor antigen. HLA-DR epitopes of CEA were identified using the epitope prediction program, PIC (predicted IC50) and tested using in vitro HLA-DR binding assays. Following CEA epitope confirmation, IFN-γ ELIspot assays were used to detect existing immunity against the HLA-DR epitope panel of CEA in breast and ovarian cancer patients. In vitro generated peptide-specific CD4 T cells were used to determine whether the epitopes are naturally processed from CEA protein. Forty-three epitopes of CEA were predicted, 15 of which had high binding affinity for 8 or more common HLA-DR molecules. A degenerate pool of four, HLA-DR restricted 15 amino acid epitopes (CEA.24, CEA.176/354, CEA.488, and CEA.653) consisting of two novel epitopes (CEA.24 and CEA.488) was identified against which 40% of breast and ovarian cancer patients had pre-existent T cell immunity. All four epitopes are naturally processed by antigen-presenting cells. Hardy-Weinberg analysis showed that the pool is useful in ~94% of patients. Patients with breast or ovarian cancer demonstrate pre-existent immune responses to the tumor antigen CEA. The degenerate pool of CEA peptides may be useful for augmenting CD4 T cell immunity.

AB - CD4 T cells are important for anti-tumor immune responses. Aside from their role in the activation of CD8 T cells, CD4 T cells also mediate anti-tumor immune responses by recruiting innate immune effectors into the tumor microenvironment. Thus, the search for strategies to boost CD4 T cell immunity is an active area of research. Our goal in this study was to identify HLA-DR epitopes of carcinoembryonic antigen (CEA), a commonly over-expressed tumor antigen. HLA-DR epitopes of CEA were identified using the epitope prediction program, PIC (predicted IC50) and tested using in vitro HLA-DR binding assays. Following CEA epitope confirmation, IFN-γ ELIspot assays were used to detect existing immunity against the HLA-DR epitope panel of CEA in breast and ovarian cancer patients. In vitro generated peptide-specific CD4 T cells were used to determine whether the epitopes are naturally processed from CEA protein. Forty-three epitopes of CEA were predicted, 15 of which had high binding affinity for 8 or more common HLA-DR molecules. A degenerate pool of four, HLA-DR restricted 15 amino acid epitopes (CEA.24, CEA.176/354, CEA.488, and CEA.653) consisting of two novel epitopes (CEA.24 and CEA.488) was identified against which 40% of breast and ovarian cancer patients had pre-existent T cell immunity. All four epitopes are naturally processed by antigen-presenting cells. Hardy-Weinberg analysis showed that the pool is useful in ~94% of patients. Patients with breast or ovarian cancer demonstrate pre-existent immune responses to the tumor antigen CEA. The degenerate pool of CEA peptides may be useful for augmenting CD4 T cell immunity.

KW - Helper T cells

KW - HLA-DR

KW - MHC class II

KW - Peptides

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=70350113820&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350113820&partnerID=8YFLogxK

U2 - 10.1007/s00262-009-0738-z

DO - 10.1007/s00262-009-0738-z

M3 - Article

VL - 59

SP - 161

EP - 171

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 1

ER -